INOVIO PHARMACEUTICALS, INC. — Form 8-K
Filed August 12, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 62/100
What the filing says
INOVIO reported Q2 2026 results with FDA's INO-3107 BLA advancing toward PDUFA target date of October 30, 2026 under accelerated approval pathway. The company raised ~$18.3M net in July 2026 equity offering and reported cash/equivalents/short-term investments of $36.7M as of June 30 (excluding July proceeds), with guidance that total resources will fund operations into late Q1 2027 through potential INO-3107 launch. Net loss for Q2 was $6.0M ($0.07/share) vs. $23.5M prior year, primarily due to $13.9M non-cash warrant liability gain; R&D and G&A expenses both decreased year-over-year.
Why this rating
INO-3107 regulatory progress and commercial prep are material for ~$74M company; $18.3M capital raise is 25% of market cap. Cash runway concern offset by near-term approval catalyst and expense discipline.
See more from August 12, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.